We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Experts: Pacira Settlement Suggests FDA Is Gun-Shy About Off-Label Challenges
Experts: Pacira Settlement Suggests FDA Is Gun-Shy About Off-Label Challenges
Legal experts say the FDA’s off-label regulation of pharmaceuticals may be on shaky ground after it agreed to settle with Pacira Pharmaceuticals this week in a case involving the pain drug Exparel.